PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23714662-9	2013	Statistically, the expression of p-ERK, P-gp and Topo IIa in the Sorafenib group was significantly reduced compared with that of the control group (P < 0.05), and there was no significant difference in the expression of p-ERK, P-gp and Topo IIa between the sorafenib group and the combination treatment group (P > 0.05).	Sorafenib	65-74	phosphoglycolate phosphatase	Mus musculus	40-44	
23714662-10	2013	CONCLUSIONS: Sorafenib can inhibit not only the tumor growth and lung metastsis in the nude mouse models, but also reduce the expression of multidrug resistance proteins P-gp and Topo IIa as well.	Sorafenib	13-22	phosphoglycolate phosphatase	Mus musculus	170-174	
20103600-3	2010	Sorafenib was moderately transported by P-gp and more efficiently by ABCG2 and Abcg2.	Sorafenib	0-9	phosphoglycolate phosphatase	Mus musculus	40-44	
21419625-0	2011	[11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice.	Sorafenib	5-14	phosphoglycolate phosphatase	Mus musculus	76-80	
20413726-0	2010	In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.	Sorafenib	67-76	phosphoglycolate phosphatase	Mus musculus	93-107	
20413726-3	2010	To evaluate the influence of P-gp on the pharmacokinetics of sorafenib substrate properties for this transporter were investigated.	Sorafenib	61-70	phosphoglycolate phosphatase	Mus musculus	29-33	
20413726-11	2010	In conclusion, sorafenib is highly permeable and a weak P-gp substrate in vitro.	Sorafenib	15-24	phosphoglycolate phosphatase	Mus musculus	56-60	
20413726-14	2010	Because of the high permeability and low P-gp-mediated transport, sorafenib might be able to cross the blood-brain barrier and target tumors within the brain.	Sorafenib	66-75	phosphoglycolate phosphatase	Mus musculus	41-45	
22335402-5	2012	The brain efflux index method, combined with the organotypic brain slices, was used to determine the net contribution of P-gp and BCRP to the total clearance of sorafenib out of the brain and show that its efflux at the BBB is mediated primarily by BCRP.	Sorafenib	161-170	phosphoglycolate phosphatase	Mus musculus	121-125	
22335402-9	2012	In conclusion, this study explains the cooperation of P-gp and BCRP by analysis of the efflux clearance of sorafenib and correlating it to the "mechanisms" that determine the clearance, i.e., affinity and capacity.	Sorafenib	107-116	phosphoglycolate phosphatase	Mus musculus	54-58	
20952483-5	2011	Sorafenib inhibited P-gp, but did not seem to be a P-gp substrate in vitro.	Sorafenib	0-9	phosphoglycolate phosphatase	Mus musculus	20-24	
20952483-10	2011	This study shows that BCRP and P-gp together restrict the brain distribution of sorafenib with BCRP playing a dominant role in the efflux of sorafenib at the BBB.	Sorafenib	80-89	phosphoglycolate phosphatase	Mus musculus	31-35